Subcutaneous injections of IL-2 decrease PD-1 expression in CD4+ and CD8+ T cells.

<p>(A) Gating strategy for CD4<sup>+</sup> HLA-DR<sup>+</sup>CD38<sup>+</sup> and CD8<sup>+</sup> HLA-DR<sup>+</sup>CD38<sup>+</sup> cell frequencies measured at wk0, wk16 and wk36. Cells were first gated on CD3+CD4+ before depicting CD38+HLA-DR+ subset. (B) Gating strategy for CD4<sup>+</sup>CD95<sup>+</sup>PD-1<sup>+</sup> and CD8<sup>+</sup>CD95<sup>+</sup>PD-1<sup>+</sup> cell frequencies that were measured at wk0, wk16 and wk36. CD3<sup>+</sup>CD4<sup>+</sup> cells were first selected, then CD95<sup>+</sup> cell gate applied and finally PD-1+ cells were depicted. Bottom panel shows Mean Fluorescence Intensity (MFI) for PD-1 on CD95+CD4+ and CD95<sup>+</sup>CD8<sup>+</sup>. Prism 5.0, version 5.0d, (GraphPad Software, Inc.) was used for statistical analyses. P values were considered significant when < 0.05.</p>